nach oben

07.05.2024 | Review

A systematic review and meta-analysis of the morbidity of efficacy endpoints and bleeding events in elderly and young patients treated with the same dose rivaroxaban

verfasst von: Jianwei Ren, Na Wang, Xuan Zhang, Fuyu Song, Xin Zheng, Xiaohong Han

Einloggen, um Zugang zu erhalten

Abstract

Rivaroxaban is a new direct oral anticoagulant, and the same dose is recommended for older and young patients. However, recent real-world studies show that older patients may need dose adjustment to prevent major bleeding. At present, the evidence for dose adjustment in older patients is extremely limited with only a few reports on older atrial fibrillation patients. The aim of this study was to review the morbidity data of adverse events and bleeding events across all indications for older and young patients treated with the same dose of rivaroxaban to provide some support for dosage adjustment in older patients. The PubMed, EMBASE, ClinicalTrials, Cochrane and Web of Science databases were searched for randomized controlled trials (RCTs) published between January 1, 2005, and October 10, 2023. The primary outcomes were the morbidity of bleeding events and efficacy-related adverse events. Summary estimates were calculated using a random effects model. Eighteen RCTs were included in the qualitative analysis. The overall morbidity of primary efficacy endpoints was higher in older patients compared to the young patients (3.37% vs. 2.60%, χ² = 5.24, p = 0.022). Similarly, a higher morbidity of bleeding was observed in older patients compared to the young patients (4.42% vs. 6.03%, χ² = 13.22, p < 0.001). Among all indications, deep vein thrombosis, pulmonary embolism and atrial fibrillation were associated with the highest incidence of bleeding in older patients, suggesting that these patients may be most need dose adjustment. Patients older than 75 years may require extra attention to prevent bleeding. The same dose of rivaroxaban resulted in higher bleeding morbidity and morbidity of efficacy-related adverse events in older patients compared to the young patients. An individualized dose adjustment may be preferred for older patients rather than a fixed dose that fits all.

Nur mit Berechtigung zugänglich

Kvasnicka T et al (2017) Rivaroxaban - Metabolism, Pharmacologic properties and Drug interactions. Curr Drug Metab 18(7):636–642PubMedCrossRef

Connolly SJ et al (2013) The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 128(3):237–243PubMedCrossRef

Schulman S et al (2013) Extended use of Dabigatran, Warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709–718PubMedCrossRef

Stein PD et al (2004) Venous thromboembolism according to age: the impact of an Aging Population. Arch Intern Med 164(20):2260–2265PubMedCrossRef

Bayer Inc. Xarelto Product Monograph Including Patient Medication Information (2022) Available online: https://www.bayer.com/sites/default/files/2020-11/xarelto-pm-en.pdf (accessed on 15 November 2022)

Steffel J et al (2021) European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace, 2021. 23(10): pp. 1612–1676

Cheung CC et al (2021) Management of Atrial Fibrillation in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines. Can J Cardiol 37(10):1607–1618PubMedCrossRef

January CT et al (2019) AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation, 2019. 140(2): pp. e125-e151

Bando S et al (2018) Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol 71(2):197–201PubMedCrossRef

10.

Fauchier L et al (2020) Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. EP Europace 22(2):205–215PubMed

11.

Hou H et al (2020) Analysis of effectiveness, Safety, and bleeding related to Rivaroxaban in Elderly patients. Clinical and Applied Thrombosis/Hemostasis, p 26

12.

Alamneh EA, Chalmers L, Bereznicki LR (2016) Suboptimal use of oral anticoagulants in Atrial Fibrillation: has the introduction of direct oral anticoagulants Improved Prescribing practices? Am J Cardiovasc Drugs 16(3):183–200PubMedCrossRef

13.

Nguyen E et al (2016) Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin 32(7):1277–1279PubMedCrossRef

14.

Kim I-S et al (2018) Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol 72(2):105–112PubMedCrossRef

15.

Sardar P et al (2014) New oral anticoagulants in Elderly adults: evidence from a Meta-analysis of Randomized trials. J Am Geriatr Soc 62(5):857–864PubMedCrossRef

16.

Lobraico-Fernandez J, Baksh S, Nemec E (2019) Elderly bleeding risk of direct oral anticoagulants in Nonvalvular Atrial Fibrillation: a systematic review and Meta-analysis of Cohort studies. Drugs R D 19(3):235–245PubMedPubMedCentralCrossRef

17.

Hanon O et al (2021) Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart 107(17):1376–1382PubMedCrossRef

18.

Wang K-L et al (2016) Standard dose versus low dose non–vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a meta-analysis of contemporary randomized controlled trials. Heart Rhythm 13(12):2340–2347PubMedCrossRef

19.

Mu G et al (2022) Standard- vs. low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis. Eur J Clin Pharmacol 78(2):181–190PubMedCrossRef

20.

Jiangya L et al (2022) Meta-analysis of the efficacy and safety of low-dose rivaroxaban in Asian patients with non-valvular atrial fibrillation. Chin Pharmacist 25(07):1183–1188

21.

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions (2009) Explanation and elaboration. Ann Intern Med, 151(4): p. W-65-W-94.

22.

Higgins JP et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 343

23.

Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129CrossRef

24.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef

25.

Schulman S et al (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202–204PubMedCrossRef

26.

International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH). Topic E7 Note for Guidance on Studies to Support of Special Populations: Geriatrics (1994) Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf (accessed on 15 November 2022). [Z]

27.

Lip GY, Halperin JL (2010) Improving stroke risk stratification in atrial fibrillation. Am J Med 123(6):484–488PubMedCrossRef

28.

Eriksson BI et al (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 358(26):2765–2775PubMedCrossRef

29.

Kakkar AK et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39PubMedCrossRef

30.

Lassen MR et al (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786PubMedCrossRef

31.

Turpie AGG et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680PubMedCrossRef

32.

Oral Rivaroxaban for Symptomatic Venous Thromboembolism (2010) N Engl J Med 363(26):2499–2510CrossRef

33.

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism (2012) N Engl J Med 366(14):1287–1297CrossRef

34.

Patel MR et al (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 365(10):883–891PubMedCrossRef

35.

Cohen AT et al (2013) Rivaroxaban for Thromboprophylaxis in acutely Ill medical patients. N Engl J Med 368(6):513–523PubMedCrossRef

36.

Mega JL et al (2011) Rivaroxaban in patients with a recent Acute Coronary Syndrome. N Engl J Med 366(1):9–19PubMedCrossRef

37.

Weitz JI et al (2017) Rivaroxaban or Aspirin for Extended treatment of venous thromboembolism. N Engl J Med 376(13):1211–1222PubMedCrossRef

38.

Mega JL et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29–38PubMedCrossRef

39.

Khorana AA et al (2019) Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory patients with Cancer. N Engl J Med 380(8):720–728PubMedCrossRef

40.

Yasuda S et al (2019) Antithrombotic therapy for Atrial Fibrillation with stable coronary disease. N Engl J Med 381(12):1103–1113PubMedCrossRef

41.

Gibson CM et al (2016) Prevention of bleeding in patients with Atrial Fibrillation undergoing PCI. N Engl J Med 375(25):2423–2434PubMedCrossRef

42.

Spyropoulos AC et al (2018) Rivaroxaban for Thromboprophylaxis after hospitalization for medical illness. N Engl J Med 379(12):1118–1127PubMedCrossRef

43.

Eikelboom JW et al (2017) Rivaroxaban with or without aspirin in stable Cardiovascular Disease. N Engl J Med 377(14):1319–1330PubMedCrossRef

44.

Krantz MJ et al (2021) Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J 42(39):4040–4048PubMedCrossRef

45.

Wen H-N et al (2022) Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res 218:24–34PubMedCrossRef

46.

Caldeira D et al (2019) Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr 81:209–214PubMedCrossRef

47.

Deng K et al (2020) Efficacy and safety of direct oral anticoagulants in Elderly patients with Atrial Fibrillation: A Network Meta-Analysis. Front Med, 7

48.

Silverio A et al (2021) Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. Eur Heart J - Cardiovasc Pharmacotherapy 7(FI1):f20–f29CrossRef

49.

Grillo JA, Bullock JM, Mehrotra N, Garnett C, Zhao P, Center for Drug Evaluation and Research (2010) US Food and Drug Administration,. Clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf. Accessed March 28, 2023

50.

Jiang J et al (2010) Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb Haemost 103(01):234–241PubMedCrossRef

51.

Kaneko M et al (2013) Confirmation of model-based dose selection for a Japanese phase III study of Rivaroxaban in Non-valvular Atrial Fibrillation patients. Drug Metab Pharmacokinet 28(4):321–331PubMedCrossRef

52.

Suzuki S et al (2018) An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metab Pharmacokinet 33(4):188–193PubMedCrossRef

53.

Zhang F et al (2022) Population Pharmacokinetics of Rivaroxaban in Chinese patients with Non-valvular Atrial Fibrillation: a prospective Multicenter Study. Clin Pharmacokinet 61(6):881–893PubMedCrossRef

54.

Zhang D et al (2023) Population Pharmacokinetics and hemorrhagic risk analysis of Rivaroxaban in Elderly Chinese patients with Nonvalvular Atrial Fibrillation. J Clin Pharmacol 63(1):66–76PubMedCrossRef

55.

Kubitza D et al (2006) The Effect of Extreme Age, and gender, on the Pharmacology and Tolerability of Rivaroxaban - an oral, direct factor xa inhibitor. Blood 108(11):905CrossRef

56.

Speed V et al (2020) Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. J Thromb Haemost 18(9):2296–2307PubMedCrossRef

Titel: A systematic review and meta-analysis of the morbidity of efficacy endpoints and bleeding events in elderly and young patients treated with the same dose rivaroxaban
verfasst von: Jianwei Ren
Na Wang
Xuan Zhang
Fuyu Song
Xin Zheng
Xiaohong Han
Publikationsdatum: 07.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05767-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen